ClinicalTrials.gg
CompletedNCT03359395Updated Jul 8, 2021Results posted

Pre-medication With Alfentanil vs Placebo During ECT

A Phase 4 interventional study of Alfentanil and Placebos in Blood Pressure and Electroconvulsive Therapy, sponsored by Wake Forest University Health Sciences. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-08.

Sponsored by Wake Forest University Health Sciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Hemodynamic changes associated with the conduct of electroconvulsive therapy may be minimized with the administration of alfentanil as part of their anesthetic regimen. This study proposes to compare the effects in a blinded fashion. Currently alfentanil is an FDA approved drug used on a daily basis by anesthesiologists on other surgeries so this is not a new indication.

Read the detailed description

Electroconvulsive therapy is associated with brief hemodynamic alterations that in some patients may be well outside the range of normalcy and potentially dangerous to the patient (Duma A, et al). This cardiovascular response is caused by activation of the autonomic nervous system and consists of an initial parasympathetic response rapidly followed by sympathetically mediated tachycardia and hypertension. The ultra-short acting synthetic opioid alfentanil has a rapid onset and duration of action that mirrors the duration of hemodynamic perturbation associated with Electroconvulsive Therapy (ECT) while having minimal or no effect on the duration or quality of the seizure. This drug may be effective in blunting the hemodynamic perturbations associated with ECT with a minimal amount of side effects.

02

Conditions studied

  • Blood Pressure
  • Electroconvulsive Therapy

Keywords

  • Anesthesia
03

In context

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,352 studies on the registry; 201 are open to participants now.

Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > /=18 years
  • Males or females
  • Anticipating electroconvulsive therapy to treat depressive disorder

Exclusion criteria

Exclusion Criteria:

  • Under the age of 18
  • Allergy to alfentanil
  • Allergy to other standard anesthetic medications utilized in the course of ECT (glycopyrrolate, methohexital, and succinylcholine)
  • History of malignant hyperthermia
  • History of severe airway obstruction, bronchospasm or laryngospasm
  • History of recent myocardial infarction, ventricular arrhythmia
  • Adverse reaction to ECT requiring premedication with lidocaine or atropine
  • Non-English speaking
  • Patients unable to consent for themselves
  • Current pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Alfentanil

    Drug: Alfentanil

  • Placebo comparator
    placebo

    Drug: Placebos

Interventions

  • Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed

  • DrugPlacebos

    Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed

06

What researchers measure

Primary outcomes

  1. Systolic Blood Pressure Change

    comparison of Systolic blood pressure changes alfentanil vs placebo

    Time frame: Baseline and up to 90 minutes

Secondary outcomes

  1. Diastolic Blood Pressure Change

    comparison of diastolic blood pressure change alfentanil vs placebo

    Time frame: Baseline and up to 90 minutes

  2. Heart Rate

    comparison of heart rate change alfentanil vs placebo

    Time frame: Baseline and up to 15 seconds

  3. Heart Rate

    comparison of heart rate change alfentanil vs placebo

    Time frame: Baseline and up to 30 seconds

  4. Heart Rate

    comparison of heart rate change alfentanil vs placebo

    Time frame: 90 minutes

  5. Maximum Heart Rate

    comparison of heart rate change alfentanil vs placebo

    Time frame: Baseline and up to 90 minutes

  6. Minimum Heart Rate

    comparison of heart rate change alfentanil vs placebo

    Time frame: Baseline and up to 90 minutes

  7. Doses of Antihypertensive Medication

    comparison of amounts of medications needed to treat blood pressure between the 2 groups

    Time frame: 90 minutes

  8. Time to Return of Spontaneous Ventilation

    time to return to breathing without assistance

    Time frame: up to 90 minutes

  9. Total Time Subject Spent In-Room

    comparison of amounts time spent in-room between the 2 groups

    Time frame: up to 90 minutes

  10. Severity of Headache in the Post Anesthesia Care Unit

    comparison between alfentanil vs placebo - Subject questionnaire with scale: 0 -10 - with 10 being the worst

    Time frame: up to 90 minutes

  11. Satisfaction With the Anesthetic Post-procedure

    comparison between alfentanil vs placebo - Subject questionnaire with scale: 0-10 - with 10 being the worst

    Time frame: up to 90 minutes

07

Results

Posted Jul 8, 2021

Participant flow

First Intervention A / B
Participant flow — First Intervention A / B
MilestoneAlfentanil Then PlaceboPlacebo Then Afentanil
Started4950
Completed4647
Not completed33
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up23
Second Intervention B/A
Participant flow — Second Intervention B/A
MilestoneAlfentanil Then PlaceboPlacebo Then Afentanil
Started4647
Completed4344
Not completed33
Withdrew: Exclusion criteria01
Withdrew: Lost to follow-up32

Outcome measures

PrimarySystolic Blood Pressure Change

comparison of Systolic blood pressure changes alfentanil vs placebo

Time frame:
Baseline and up to 90 minutes
Reported as:
Mean · mmHg
Systolic Blood Pressure Change
mmHgAlfentanilPlacebo
Systolic Blood Pressure Change22.011 ± 36.96838.908 ± 33.50864
SecondaryDiastolic Blood Pressure Change

comparison of diastolic blood pressure change alfentanil vs placebo

Time frame:
Baseline and up to 90 minutes
Reported as:
Mean · mmHg
Diastolic Blood Pressure Change
mmHgAlfentanilPlacebo
Diastolic Blood Pressure Change15.26 ± 23.384850704323.34 ± 24.40
SecondaryHeart Rate

comparison of heart rate change alfentanil vs placebo

Time frame:
Baseline and up to 15 seconds
Reported as:
Mean · Beats per Minute
Heart Rate
Beats per MinuteAlfentanilPlacebo
Heart Rate26.00 ± 19.82328.197674418604 ± 21.486
SecondaryHeart Rate

comparison of heart rate change alfentanil vs placebo

Time frame:
Baseline and up to 30 seconds
Reported as:
Mean · Beats per Minute
Heart Rate
Beats per MinuteAlfentanilPlacebo
Heart Rate37.48 ± 25.4636.93 ± 25.46
SecondaryHeart Rate

comparison of heart rate change alfentanil vs placebo

Time frame:
90 minutes

No measurements were reported for this outcome.

SecondaryMaximum Heart Rate

comparison of heart rate change alfentanil vs placebo

Time frame:
Baseline and up to 90 minutes
Reported as:
Mean · Beats per Minute
Maximum Heart Rate
Beats per MinuteAlfentanilPlacebo
Maximum Heart Rate44.33 ± 24.27449.66 ± 26.629
SecondaryMinimum Heart Rate

comparison of heart rate change alfentanil vs placebo

Time frame:
Baseline and up to 90 minutes
Reported as:
Mean · Beats per Minute
Minimum Heart Rate
Beats per MinuteAlfentanilPlacebo
Minimum Heart Rate12.74 ± 14.6747.08 ± 19.221
SecondaryDoses of Antihypertensive Medication

comparison of amounts of medications needed to treat blood pressure between the 2 groups

Time frame:
90 minutes

No measurements were reported for this outcome.

SecondaryTime to Return of Spontaneous Ventilation

time to return to breathing without assistance

Time frame:
up to 90 minutes
Reported as:
Mean · Minutes
Time to Return of Spontaneous Ventilation
MinutesAlfentanilPlacebo
Time to Return of Spontaneous Ventilation8.17 ± 2.4837.25 ± 1.869
SecondaryTotal Time Subject Spent In-Room

comparison of amounts time spent in-room between the 2 groups

Time frame:
up to 90 minutes
Reported as:
Mean · Minutes
Total Time Subject Spent In-Room
MinutesAlfentanilPlacebo
Total Time Subject Spent In-Room17.51 ± 4.64016.43 ± 3.940
SecondarySeverity of Headache in the Post Anesthesia Care Unit

comparison between alfentanil vs placebo - Subject questionnaire with scale: 0 -10 - with 10 being the worst

Time frame:
up to 90 minutes
Reported as:
Mean · score on a scale
Severity of Headache in the Post Anesthesia Care Unit
score on a scaleAlfentanilPlacebo
Severity of Headache in the Post Anesthesia Care Unit2 ± 2.8872.467 ± 3.038
SecondarySatisfaction With the Anesthetic Post-procedure

comparison between alfentanil vs placebo - Subject questionnaire with scale: 0-10 - with 10 being the worst

Time frame:
up to 90 minutes
Reported as:
Mean · score on a scale
Satisfaction With the Anesthetic Post-procedure
score on a scaleAlfentanilPlacebo
Satisfaction With the Anesthetic Post-procedure8 ± 2.4498.033 ± 2.505

Adverse events

Collected over 24 hours. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alfentanil1/87 (1.1%)1/87 (1.1%)0/87 (0%)
Placebo1/87 (1.1%)1/87 (1.1%)0/87 (0%)
Most frequent serious events
Most frequent serious events
EventAlfentanilPlacebo
SuicideSocial circumstances1/871/87
Most frequent other events
Most frequent other events
EventAlfentanilPlacebo
SuicideSocial circumstances0/870/87

Baseline characteristics

Age, Continuous
Age, Continuous(years)Alfentanil Then Placebo Arm 1Placebo Then Alfentanil Arm 2Total
Mean51.34 ± 17.1051.94 ± 13.9651.621 ± 15.57
Sex: Female, Male
Sex: Female, Male(Participants)Alfentanil Then Placebo Arm 1Placebo Then Alfentanil Arm 2Total
Female353267
Male141832
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Alfentanil Then Placebo Arm 1Placebo Then Alfentanil Arm 2Total
Hispanic or Latino101
Not Hispanic or Latino484896
Unknown or Not Reported022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alfentanil Then Placebo Arm 1Placebo Then Alfentanil Arm 2Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American123
White484694
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)Alfentanil Then Placebo Arm 1Placebo Then Alfentanil Arm 2Total
United States495099
Height (cm)
Height (cm)(Centimeters)Alfentanil Then Placebo Arm 1Placebo Then Alfentanil Arm 2Total
Mean167.57 ± 11.31167.59 ± 10.25167.58 ± 10.67
Weight (kg)
Weight (kg)(kilograms)Alfentanil Then Placebo Arm 1Placebo Then Alfentanil Arm 2Total
Mean86.28 ± 31.5785.156 ± 27.3385.405 ± 30.05
08

Study locations

1 site
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
09

References and documents

Publications

  • McCutchen TM, Gligorovic PV, Tighe NTG, Templeton TW, Saha AK. Alfentanil Pretreatment for Electroconvulsive Therapy-Associated Hemodynamic Lability: A Prospective Randomized Crossover Trial. J ECT. 2023 Jun 1;39(2):84-90. doi: 10.1097/YCT.0000000000000885. Epub 2022 Oct 1. PubMed 36215414 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Feb 2020, 20 months.

Results were first posted in Jul 2021, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2017
First posted
Dec 2, 2017
StartActual
Jun 4, 2018
Primary completionActual
Feb 17, 2020
CompletionActual
Feb 17, 2020
Results first posted
Jul 8, 2021
Last update
Jul 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03359395
Responsible party
Sponsor
First posted
Dec 2, 2017
Start date
Jun 4, 2018
Primary completion
Feb 17, 2020
Completion
Feb 17, 2020
Results posted
Jul 8, 2021
Last update
Jul 8, 2021

Study contacts

Quinn McCutchen, MD
principal investigator · Wake Forest School of Medicne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alfentanil

Start the discussion